Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the decision will lift treatment adherence rates across the country.
Read More
Major Melbourne study a world-first for AMD
An Australian-led study has received $5 million to undertake the world’s most intensive investigation into why a particular group of age-related macular degeneration (AMD) patients are at greater risk of vision loss.
Read More
Read More